ESMO Open: A first-line regimen of paclitaxel combined with carboplatin plus bevacizumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma

So far, the value of anti- angiogenic antibody therapy in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) is still unclear
.

Professor Huang Yan from the Department of Oncology, Sun Yat-sen University Cancer Center led his team and partners to conduct a phase 2 clinical trial to evaluate the feasibility of paclitaxel combined with carboplatin plus bevacizumab in the treatment of recurrent or metastatic nasopharyngeal carcinoma Sex

Blood vessel

A total of 80 untreated patients with recurrent/metastatic nasopharyngeal carcinoma were recruited and randomly (1:1) divided into two groups to receive paclitaxel (175 mg/m2) combined with carboplatin + bevacizumab (CPB group) ) Or paclitaxel combined with carboplatin (CP group) for up to 6 consecutive courses
.

The primary endpoint is the progression-free survival (PFS) assessed by the investigator, and the secondary endpoints are the progression-free survival, overall survival (OS), objective response rate (ORR), and safety assessed by the independent committee

Progression-free survival in both groups

Progression-free survival in both groups

The median progression-free survival estimated by investigators in the CPB group and CP group were 7.
5 months (95% CI 6.
53-8.
45) and 6.
5 months (95% CI 5.
53-7.
52; P=0.
0148), respectively.
The progression survival period is similar to this
.

The median overall survival of CPB group and CP group was also similar (21.

The tumor shrinkage rate of the CPB group was significantly higher than that of the CP group .

Overall survival of the two groups

Overall survival of the two groups

There was no significant difference in adverse events of grade 3 and above between the two groups
.

In summary, in the first-line regimen of paclitaxel combined with carboplatin, the addition of bevacizumab cannot prolong the progression-free survival and overall survival of patients with recurrent or metastatic nasopharyngeal carcinoma, but it can increase the tumor shrinkage rate.

.

The results of this study suggest that bevacizumab combined with chemotherapy may be used as an alternative for nasopharyngeal carcinoma with large tumor volume or seeking short-term effects of neoadjuvant chemotherapy and concurrent chemotherapy

In the first-line regimen of paclitaxel combined with carboplatin, the addition of bevacizumab cannot prolong the progression-free survival and overall survival of patients with recurrent or metastatic nasopharyngeal carcinoma, but it can increase the tumor shrinkage rate

Original source:

Zhou T,Yang Y,Ma S et al.

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II tria in this message